Mesa Laboratories Inc. (NASDAQ: MLAB) has experienced notable developments regarding its executive leadership and insider trading activity. Lyndsey Elizabeth Crennen, serving as the company's Chief Accounting Officer, executed a sale of 442 shares of the firm's common stock on June 22, 2026. The transaction was valued at $89.502 per share, resulting in a total proceeds amount of $39,559. According to regulatory filings, these shares were liquidated to satisfy tax obligations associated with the vesting of Restricted Stock Units (RSUs) and Performance Share Units (PSUs) that occurred on June 18, 2026. The sale was conducted in accordance with a Rule 10b5-1 trading plan.
Before executing the sale, Ms. Crennen acquired a total of 989 shares of Mesa Laboratories common stock on June 18, 2026. This acquisition comprised 726 shares obtained through the conversion of Restricted Stock Units at a price of $95.1 per share, totaling $69,042. These RSUs represented a contingent right to receive one share of common stock and were scheduled to vest on various dates, including June 21, 2024, June 18, 2025, and June 19, 2025. Additionally, Ms. Crennen received 263 shares of common stock, valued at $25,011 at a price of $95.1 per share, upon the release of performance share units issued under the company's FY24-FY26 program.
Following these transactions, Ms. Crennen directly holds 2,020 shares of Mesa Laboratories Inc. common stock. The insider activity occurs against a backdrop of recent market performance for Mesa Laboratories stock, which has declined 6.5% over the past week. Despite this recent decline, the company currently trades at $93.75 with a market capitalization of $518.9 million. According to InvestingPro analysis, the stock appears undervalued based on Fair Value calculations, with a PEG ratio of just 0.17 suggesting attractive growth potential relative to its earnings multiple.
In other recent developments, Mesa Laboratories reported that its fourth-quarter results did not meet expectations, with revenues falling 2% below consensus estimates. The company's Biological Products Division experienced a significant 32% decline in core revenue, which was attributed to export-control related shipping delays and poor commercial execution. In response to these developments, Jefferies raised its price target for Mesa Laboratories to $130 from $115 while maintaining a Buy rating, reflecting optimism about the company's future under its current leadership.
Additionally, Mesa Laboratories announced a planned transition in its executive leadership, with President and CEO Gary Owens set to depart in April 2026. Owens will remain in a non-executive role until June 2026 to assist with the transition. Under a Retention and Transition Agreement, he will receive severance pay and retain a portion of his performance stock unit award, subject to performance conditions. Furthermore, the company appointed Lyndsey Crennen as the new chief accounting officer. Crennen, who joined Mesa Laboratories in 2018, brings over 20 years of accounting experience to her new role. These developments are part of ongoing changes within the company.